MEDICINE: AWARD DRAWS INTEREST TO FIRM’S NEW DRUG
NIH Grant Gives OrPro More Than Just Money
Monday, August 13, 2012
ORPRO THERAPEUTICS INC.
CEO: Peter Heifetz.
Revenue: Pre-revenue.
No. of local employees: Two full-time, supplemented by consultants and advisers.
Investors: Self-funded.
Headquarters: San Diego.
Year founded: 2011.
Company description: Preclinical stage biopharmaceutical company developing recombinant thioredoxin for the treatment of cystic fibrosis and other obstructive pulmonary diseases.
Key factors for success: Backing by National Institutes of Health. Has assembled ‘world-class’ team of experts to advise on research, development, manufacturing and financing.
A monetary ripple in the funding waters could bring a wave of change to OrPro Therapeutics Inc...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know